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1. Introduction 
Colorectal carcinoma (CRC) is the second most common cancer in women after carcinoma of 
the breast and the third most common cancer in men after carcinoma of the prostate and 
lung with a lifetime risk in the UK of one in 16 for men and one in 20 for women (C-R-UK, 
2011). In 2008, around 40,000 people in the UK were diagnosed with bowel cancer and 
approximately 16,000 died from the disease. In the same year, there were an approximately 
334,000 new cases of CRC in the European Union (GLOBOCAN, 2008). The lowest rates for 
both men and women were in Greece and the highest rates for men were in Hungary and 
for women in Denmark. Rates for the UK for men and women were below the EU27 average 
(C-R-UK, 2011). Worldwide, every year, more than 1 million will develop CRC (Parkin et al., 
2005).  
Over 90% of CRC is sporadic in nature and affects 25 per 100 000 per year of individuals 
aged 45–55, but over 300 per 100 000 per year in individuals aged 75 and over (West et al., 
2008). Internationally, the UK has an incidence of CRC close to the average for all EU 
countries, which is slightly lower than that for Australia, New Zealand and North America 
(Halloran, 2009).  
Survival rates in individuals with CRC have increased substantially in the past few years, 
possibly as a result of early diagnosis and improved treatment. Although substantial 
information about risk factors exists, about 75% of diagnoses are in patients with no 
apparent risk factors other than old age (ACS, 2011), however, the 5-year survival is still less 
than 60% in most European countries (Verdecchia et al., 2007). 
2. Why screen for bowel cancer? 
In 1998 the NHS started to develop the Bowel Cancer Screening Programme (Hardcastle et 
al., 1996) and in 2006, the English CRC screening programme started a 2-yearly screening for 
individuals between the ages of 60 and 69 (extended to 74 years in 2010) (Halloran, 2009). 
The decision was based on the results of four large randomized controlled trials, including 
one in Nottingham (Hardcastle et al., 1996), where a 16% reduction in mortality was 
associated with the implementation of bowel screening. These trials showed that population 






reduce colorectal mortality between 15% to 18% in people aged 45-74 (Hardcastle et al., 
1996; Kronborg et al., 1996; Lindholm et al., 2008; Mandel et al., 1993). Individuals who 
attend screening have a 25% reduction in their risk of dying from CRC. These studies 
supported similar results from trials in Nottingham (Hardcastle et al., 1996; Steele et al., 
2009; UK-Colorectal-Cancer-Screening-Pilot-Group, 2004).  
The use of flexible sigmoidoscopy has also been investigated as a screening tool (Atkin et al., 
1993; UK-Flexible-Sigmoidoscopy-Screening-Trial-Investigators, 2002) which showed that a 
once-only flexible sigmoidoscopy between the ages of 55 and 64 could reduce CRC 
incidence by 33% and mortality from CRC by 43% (Atkin et al., 2010). The test was also 
found to be safe and acceptable (Atkin et al., 1993). Several randomised trials and Cochrane 
reviews have provided high-quality evidence that this test, if offered every 2 years, has the 
potential to reduce mortality rates associated with CRC by 16% (Towler et al., 1998) and 
reduces incidence and mortality rates of distal CRC by 60–80% (Newcomb et al., 2003; Selby 
et al., 1992). 
In general, the NHS Bowel Cancer Screening Programme (NHS BCSP) commenced in April 
2006 and invites men and women aged 60–69 to participate via submission of faecal occult 
blood test every 2 years; those with a positive result will be offered colonoscopy (West et al., 
2008). 
As a marker of the success of the programme, at colonoscopy, the proportion of Duke’s 
stage A and B lesions is markedly higher than that diagnosed amongst the symptomatic 
population (Goodyear et al., 2008; Halloran, 2009). 
3. Principles of screening 
The aim of screening for CRC is to prevent the development of advanced disease through 
detection of early  and premalignant adenomas, from which at least 80% of cancers are 
thought to arise (Cunningham et al., 2010). As outlined by Wilson and Jungner, (1968) the 
criteria for screening (Table 1), which have been adopted by the WHO, demonstrates that 
CRC is an ideal disease for screening. Population screening therefore continues to offer the 
best prospects for reduction in mortality rates (Cunningham et al., 2010). 
WHO screening principles: 
1. The condition sought should be an important health problem for the individual and 
community. 
2. There should be an acceptable treatment or useful intervention for patients with the 
disease. 
3. Facilities for diagnosis and treatment should be available. 
4. There should be a recognizable latent or early symptomatic stage. 
5. There should be a suitable screening test or examination. 
6. The test should be acceptable for the population. 
7. The natural history of the disease should be adequately understood. 
8. There should be an agreed policy for referral for further examination and for whom to 
treat as patients. 
9. The cost should be economically balanced in relation to possible expenditure on 
medical care as a whole. 
10. Case finding should be a continuing process and not a once-only project. 
Table 1. (Wilson and Jungner, 1968) 
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The programme uses faecal occult blood testing (FOBt) as the primary screening modality to 
select patients for colonoscopy (BCSP, 2011). Colonoscopy is the best means we have to 
detect CRC and it provides an opportunity for therapeutic intervention, which is not 
possible with virtual colonoscopy (computerized tomography colonography). CT 
colonography (virtual colonoscopy) is as sensitive as colonoscopy for the detection of 
cancers and large adenomas, but includes exposure to radiation, requires full bowel 
preparation, and, at the end, colonoscopy is necessary for definite treatment (Halligan et al., 
2005; Whitlock et al., 2008). Whilst the morbidity and mortality associated with colonoscopy 
might be considered acceptable for patients with signs and symptoms of the disease, they 
are unacceptable as a first line population screening. Perforation and clinically significant 
bleeding occur after colonoscopic polypectomy in about 0.2% and 1% of cases, respectively 
(Bond, 2000). 
Flexible sigmoidoscopy carries significantly lower risk but will miss some 30 to 40% of 
proximal lesions (Halloran, 2009). As a screening test, the guaiac FOBT (gFOBT) has 
significant limitations as it cannot detect low concentrations of blood and has a poor 
analytical specificity. Any blood that reaches the stool may give a positive test result such as 
in cases of ulcerative colitis, Crohn’s disease, haemorrhoids, major dental surgery or upper 
gastrointestinal bleeds, as does a diet of large raw steaks and black pudding (Halloran, 
2009). Evidence from randomized controlled trials designed to assess the impact of FOBt-
based screening on mortality in the screened population have suggested that FOBt is more 
likely to detect distal colonic and sigmoid lesions rather than right-sided tumours (Thomas 
et al., 1992).  
The sensitivity of FOBt varies but has been quoted as between 6.2% and 83.3% in a recent 
systematic review when considering all neoplasms (Burch et al., 2007). 
Harmston et al. (2010) showed that the location of screen-detected cancers does not differ from 
that seen in the unscreened population which suggests that faecal occult blood test screening 
detects cancer irrespective of location within the colon. It should be stressed that patients with 
negative FOB negative should not be given the impression of being cancer free.  
Hol et al. (2010) recently showed in a population-based CRC screening trial using 
immunochemical FOB (IFOB) randomized against guaiac-based FOB that the detection rate 
was far better in the former. The authors strongly suggest using the IFOB in screening 
programmes, however, these findings need to be validated before changing practice of 
screening.  
As a result of bowel screening, there will be more cases of malignant polyps detected in the 
screening programme than in symptomatic patients. Furthermore, how should patients with 
positive FOB and negative colonoscopy be managed?  
One review from Canada (McLoughlin and Telford, 2007) addressed the issue and showed 
that when there is positive FOB and the patient undergoes both upper and lower 
gastrointestinal endoscopy, the yield for upper tract pathology is significant. These authors, 
however, argue that in those patients with a positive FOB test and negative colonoscopy, it 
is not cost effective to perform routine upper endoscopy unless the patient is anaemic, 
symptomatic or has risk factors for gastric cancer.  
What happens to the population outside the screening age group?  
In an important study, Shellnut et al. (2010) looked at the appropriateness of restricting the 
screened age group and found that not screening individuals under 50 and over 75 years 
would miss around 49 to 50% of patients in their study. Harmston et al. (2010) looked at 100 






significant symptoms such as rectal bleeding, tenesmus, change in bowel habit and 
abdominal pain and they argued that with proper public awareness, these symptoms would 
have triggered referral. The study also showed that there was a significant increase in 
detecting Dukes A lesions in 28.5% of cases. 
Ellul et al. (2010) again showed that with screening there is earlier detection of Dukes A over 
a non screened population of 45.3% compared with 10.1%. This is good evidence for the 
benefit of screening. It is remarkable, however, that the proportion of Dukes A stage 
tumours varied widely from 45.3% in the study of Ellul et al. to 28.5% in that of Harmston et 
al. with no apparent explanation for this variation. The screening programme is likely to be 
an effective and practical way of reducing CRC, but it does have its limitations, which can 
only be reduced by further research to maximize overall patient care (Haboubi, 2010). 
4. Pathology and management of early (pT1) colorectal lesions in the 
NHSBCSP 
Colorectal polyps are extremely common in Western countries and are found in up to 30% 
of autopsies performed in people aged more than 60 years (Williams et al., 1982). 
Histologically, colorectal polyps are divided into neoplastic or nonneoplastic and it is well 
known that more than 95% of CRC arise from neoplastic adenomatous polyps (adenomas) 
(Bond, 2000; Morson, 1966) through the well documented adenoma–carcinoma sequence 
(Muto et al., 1975). 
By definition, all adenomas show dysplasia and is divided into either low or high grade 
(Quirke et al., 2007; Riddell et al., 1983) and architecturally into either tubular, tubulovillous 
or villous types according to the WHO classification (Hamilton and Aaltonen, 2000). High 
grade dysplasia shows complex glandular crowding and irregularity, prominent budding, 
cribriform architecture with ‘back to back’ glands and prominent cellular atypia (Quirke et 
al., 2007; Riddell et al., 1983). The latter includes loss of cell polarity or nuclear stratification, 
markedly enlarged nuclei with a dispersed chromatin pattern and a prominent nucleolus, 
abundant mitotic figures with atypical mitoses and prominent apoptosis.  
A malignant colorectal polyp is a lesion in which cancer has invaded through the muscularis 
mucosae and into the submucosa (Cooper, 1983; Cooper et al., 1995; Lipper et al., 1983; 
Morson et al., 1984; Volk et al., 1995) and T1 adenocarcinoma is defined as invasion into the 
submucosa and not into the muscularis propria (Edge et al., 2010). The incidence of 
malignant colonic polyps amongst all removed colonic adenomas varies between 2.6% and 
9.7%, with an average incidence of 4.7% (Coverlizza et al., 1989). 
Increasing dysplasia and, presumably, malignant potential correlate with increasing 
adenoma size, villous component, and patient age (Konishi and Morson, 1982). The 
likelihood of invasive carcinoma also increases with increasing polyp size (Fenoglio and 
Pascal, 1982). Size is perceived to be one of the most important risk factor which put an 
adenoma into high risk category of malignant transformation. Amongst 5137 adenomas of 
diameter of less than 5 mm, none demonstrated malignant transformation (Nusko et al., 
1997). 
Generally, malignant colorectal polyps are divided into high and low risk lesions. High risk 
malignant polyps were defined as having one of the following: incomplete polypectomy, an 
involved resection margin, lymphatic or venous invasion, or are poorly differentiated 
histologically (Netzer et al., 1997). Adverse outcome in a malignant colorectal polyp was 
defined as residual cancer in a resection specimen and local or metastatic recurrence in the 
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follow up period (Netzer et al., 1998). In the high risk group, surgery is recommended when 
either of the two independent risk factors, such as incomplete polypectomy or a positive 
margin is present or if there is a combination of other risk factors. As lymphovascular invasion 
or poorly differentiated cancer did not have an adverse outcome when studied alone, 
operations in such cases should be individually assessed taking the risk of surgery into 
consideration (Netzer et al., 1998) as the risk for death from elective colonic resection averages 
about 2% (from 0.2% in the young to  more than 5% in the elderly) (Greenburg et al., 1981).  
An analysis of published series of malignant polyps estimated that the risk of residual 
cancer or nodal metastases from endoscopically resected pedunculated and sessile 
malignant polyps with favourable criteria was 0.3% and 1.5%, respectively (Cranley et al., 
1986). Another review of endoscopically resected polyps with poor prognostic factors 
(poorly differentiated cancer, margin involvement, or presence of lymphatic or vascular 
invasion) reported residual cancer in 8.5% and 14.4%, for patients with pedunculated and 
sessile malignant polyps, respectively  (Coverlizza et al., 1989). The American College of 
Gastroenterologist recommends no further treatment if the polyp is considered to be 
completely excised by the endoscopist, the cancer is not poorly differentiated and there is no 
vascular or lymphatic permeation and the margin of excision is free (Bond, 2000). Invasion 
of the stalk of a pedunculated polyp, by itself, is not an unfavorable prognostic finding, as 
long as the cancer does not extend to the margin of resection (Bond, 2000). In large sessile 
polyps which are not resectable endoscopically or that might contain invasive carcinoma 
with unfavorable prognostic features, it is useful to mark the polypectomy site (Shatz et al., 
1997) to aid future identification of the site if necessary. 
If the polyp is removed in one piece, the area of diathermy can be used as the histological 
landmark for the true transected margin of resection. If the polypectomy has been performed 
in piecemeal, it may be impossible to determine the true margin of resection, therefore 
precluding an accurate reporting on the status of completeness of excision (Cooper, 2007). 
The presence of multiple adenomas in the same segment as the malignant polyp might be an 
argument for resection, particularly if the other polyps subsequently show high grade 
dysplasia (Haboubi and Scott, 2000). Similarly, the presence of a malignant adenoma in 
association with a strong family history of large bowel cancer would also be in favour of 
resection (Haboubi and Scott, 2000). 
4.1 Factors against resection 
Surgical resection is associated with a significant risk of mortality and morbidity with the risk 
of diarrhea after extensive colonic resection, particularly in the elderly (Haboubi and Scott, 
2000) with an overall mortality of 5% (Scott et al., 1995). In practice, any individual patient 
with a histologically unfavourable malignant polyp has either a 10% chance of cancer-specific 
treatment failure or a 3-5% risk of postoperative death (Haboubi and Scott, 2000). 
4.2 Margins of excision 
Cancer at or near the resection margin is a histological finding that signifies the potential for 
an adverse outcome (Hackelsberger et al., 1995; Hassan et al., 2005; Ueno et al., 2004a). In 
one study, 21.4% of cases with cancer at or near the resection margin had an adverse 
outcome (Cooper et al., 1995). It is also important to record completeness of excision of the 
deep and mucosal margins as surgery is usually an indication when the former is involved 
and further local excision may be tempted if the mucosal margin is believed to be involved 






An involved margin has many definitions in the literature. Cancer near the margin has been 
variously defined as cancer cells 1mm or less from the transacted margin, (Cooper et al., 
1995) cancer cells 2mm or less from the transacted margin, (Netzer et al., 1997; Volk et al., 
1995) and cancer within the diathermy and/or within one high-power field of the diathermy 
(Morson et al., 1984; Ueno et al., 2004b). However, most studies showed that the presence of 
cancer near the transected margin has the same clinical significance as cancer at the actual 
margin (Cooper et al., 1995; Hackelsberger et al., 1995; Netzer et al., 1997). 
Presently, there is no consensus on what represents a ‘negative margin’. A negative margin 
has been defined as one in which cancer is not within the actual diathermy, (Morson et al., 
1984) more than one high-power field from the diathermy, greater than 1mm from the 
margin (Cooper et al., 1995) and more than 2mm from the margin (Netzer et al., 1997; Seitz 
et al., 2004). Incomplete local excision is not a judgement based on histology alone but a 
decision made jointly by the endoscopist and pathologist (Cooper, 2007). 
4.3 Histological grade 
Poorly differentiated (grade III) cancer, which has been classified as a poor risk factor in a 
malignant polyp, comprise 5–10% of cases and are associated with a significantly greater 
incidence of poor outcome than for better differentiated tumours (Kyzer et al., 1992; 
Nivatvongs et al., 1991).  
4.4 Vascular invasion 
Many studies showed that vascular invasion has been associated with an adverse outcome 
(Hassan et al., 2005; Ueno et al., 2004b). Muller et al. (Muller et al., 1989) demonstrated that 
vascular invasion on its own predicted an adverse outcome, but other studies have not 
supported these findings (Cooper et al., 1995; Volk et al., 1995): 
4.5 Haggitt levels 
Haggitt level of invasion in a pedunculated polyp is an important risk factor. In the Haggitt 
system (Haggitt et al., 1985) the level of invasion in a malignant pedunculated polyp is 
defined as follows: 
Level 1: Carcinoma invading into the submucosa, but limited to the head of the polyp.  
Level 2: Carcinoma invading to the level of the neck (the junction of the head and stalk) of 
the adenoma.  
Level 3: Carcinoma invading any part of the stalk.  
Level 4: Carcinoma invading into the submucosa of the bowel wall below the level of the 
stalk but above the muscularis propria.  
According to these criteria, invasive cancer arising in a pedunculated adenoma could be 
classified as level 1 to level 4, but invasive cancer arising in a sessile adenoma is by 
definition a level 4 lesion. Studies have shown that level 4 invasion correlates with an 
adverse outcome and that patients with level 1–3 cancers and grade I or II cancers, and no 
lymphatic or venous invasion, can be successfully treated by polypectomy alone (Haggitt et 
al., 1985; Pollard et al., 1992). 
Follow-up surgical resection has been recommended following polypectomy showing 
Haggitt level 4 invasion (Haggitt et al., 1985; Kyzer et al., 1992; Nivatvongs et al., 1991) or 
with any level polyp with grade III cancer, (Pollard et al., 1992) and/or lymphatic invasion 
(Haggitt et al., 1985). 
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4.6 Kikuchi’s levels 
In pT1 tumours, the frequency of lymph node metastasis in sessile tumours that involve the 
superficial, middle and deep thirds of the submucosa (so-called Kikuchi levels sm1, sm2 and 
sm3 respectively) (Kikuchi et al., 1995) has been reported to be 2%, 8% and 23% respectively 
(Nascimbeni et al., 2002). Invasion to level SM1 has been reported to have a significantly lower 
incidence of lymph node metastasis than level SM2 or SM3 invasion (Nascimbeni et al., 2002).  
However, neither the Kikuchi (for sessile tumours) nor the Haggitt (for polypoid tumours) 
system is easy to interpret, especially if there is fragmentation or suboptimal orientation of 
the polyp.  
More recently, Ueno et al. (Ueno et al., 2004b) proposed that the depth of invasion measured 
in microns beyond the muscularis mucosae provides a more objective measure, and this 
system has been adopted in Japan. However, again this system is difficult to use in routine 
practice. 
It has to be highlighted that each classification has advantages and disadvantages. The 
Kikuchi system cannot be used if there is no muscularis mucosa in the biopsy and the 
Haggitt system is of no value in sessile lesions and measurement depends on a recognisable 
submucosa and good orientation of the polyp (Quirke et al., 2007). 
In an extensive review of the literature (31 studies involving 1900 patients), Hassan et al. 
(2005) reported god outcome in polyps showing favourable histological features (e.g. 
negative margin, grade I or II and absence of lymphovascular invasion), supporting the 
suggestion that endoscopic polypectomy alone is adequate treatment in these patients.  
The treatment of patient with an endoscopically removed malignant colorectal polyp must 
be individualized for each patient, taking all factors into consideration. Guidelines endorsed 
by the American Gastroenterological Association (Bond, 2000) recommend no further 
treatment is indicated after colonoscopic resection of a malignant colorectal polyp if the 
following criteria are fulfilled:  
• The polyp is considered by the endoscopist to have been completely excised 
• The cancer is not poorly differentiated 
• There is no vascular or lymphatic permeation 
• The margin of excision is not involved.  
The guidelines also comment that when a patient’s malignant polyp has poor prognostic 
features, the relative risks of surgical resection should be weighed against the risk of death 
from metastatic cancer. 
4.7 Tumour budding 
Tumour budding is defined as isolated single cancer cells or small clusters (fewer than five 
cells) of cancer cells at the advancing edge of the tumour. Several studies have defined a 
tumour as positive for budding when there are five or more buds per 20 power field 
(Kaneko et al., 2007; Ueno et al., 2004b). Studies of T1 cancers have shown that the presence 
of tumour budding is significantly associated with lymph node metastasis and other 
adverse outcomes (Kaneko et al., 2007; Masaki et al., 2001a; Ueno et al., 2004b). 
4.8 Cribriform histology 
T1 CRC with a cribriform histology showed a high rate of lymph node metastasis when 
analyzed with multivariate analysis. In one of the studies, all the cases were all initially 






4.9 Potential ‘molecular’ markers 
Masaki et al. (Masaki et al., 2001b) showed that expression of MMP-7 (a matrix 
metalloproteinase) at the invasive margin of T1 cancers was significantly associated with 
other poor histological features and unfavourable outcome. Hirano and Minimoto (2000) 
reported that a high expression of p53 and a low expression of p27 were significantly 
associated with metastasis in cases of T1 CRC. 
4.10 Pseudoinvasion/misplaced mucosa 
Pseudoinvasion is misplacement of the whole mucosa into the submucosa and this 
herniated mucosa often mimics invasive cancer causing a diagnostic difficulty for 
pathologists. Even among experienced gastrointestinal pathologists, there is a lack of 
unanimity in differentiating invasive carcinoma from pseudoinvasion (Cooper et al., 1995; 
Muto et al., 1973). It is commonly seen in prolapsed polyps in the sigmoid colon and is 
perceived to be one of the most difficult areas in the interpretation of polyp and in the 
context of the bowel screening programme (Quirke et al., 2007). 
In cases of pseudoinvasion, the rounded contour of the neoplastic glands and the cytological 
similarity of the herniated epithelium to the surface adenoma, continuity of the surface 
epithelium with the ‘deep’ epithelium and the presence of lamina propria around the 
submucosal are all indications of pseudoinvasion rather than invasive cancer (Cooper, 2007). 
The presence of haemosiderin deposits provides a clue to the presence of misplaced 
epithelium. The distinction between invasion and pseudoinvasion is made more difficult 
when the herniated epithelium is severely dysplastic (Pascal et al., 1990) and there are 
instances where the differentiation is difficult with 100% certainty and the pathology report 
should indicate this uncertainty. 
4.11 Serrated lesions of the colorectum 
Serrated lesions have only recently been highlighted as having distinct genetic features and 
a different architecture from classical adenomas. The family of serrated polyps comprises 
sessile serrated adenomas, also called sessile serrated polyps (SSA/Ps), traditional serrated 
adenomas, hyperplastic polyps, and mixed hyperplastic/adenomatous polyps or admixed 
polyps (Ensari et al., 2010). 
It is estimated that SSA/Ps represent 8-20% of serrated polyps with a predilection for the 
right colon. The diagnosis is mainly based on architectural features and are usually larger 
than hyperplastic polyps, measuring from 5 mm to more than 10 mm. They are flat to 
sessile. The crypts are elongated and epithelial serration and dilatation are usually more 
prominent in the basal part of the crypts in a ‘crescendo’ fashion.  
Traditional hyperplastic polyps that are large (>1 cm) and/or multiple and/or located in the 
proximal colon are associated with an increased risk for CRC, notably in the hyperplastic 
polyposis syndrome where they occur throughout the colon with a 50% risk of CRC (Leggett 
et al., 2001). From the management point of view they should be treated similar to 
conventional adenomas. 
5. Conclusion 
The histopathology reports on malignant colorectal specimens are of major importance 
regarding patient management, prognostic assessment, audit and research. It has been 
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shown that use of proforma greatly improves the quality of such reports (Quirke et al., 2007; 
Quirke and Morris, 2007). 
The bowel cancer screening programme will generate many early cancers (pT1) for which 
there is poor management protocols as opposed to pT2 tumours which they need a definite 
surgical excision (Haboubi, 2010; Quirke et al., 2007). 
The preferred care for patients with polypectomy specimens which contain invasive 
carcinoma is controversial (Haboubi and Scott, 2000). Taking into considerations all factors 
involved, the issue of polypectomy for malignant polyps versus surgical resection is best 
resolved by a multidisciplinary team involving the surgeon, pathologist and endoscopist, 
taking the patient's condition and wishes into account (Mitchell and Haboubi, 2008). 
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